IMTX - Immatics NV logo

Immatics NV

IMTX

Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors. Its product pipeline includes various cell therapies and bispecifics in clinical trials, partnering with institutions to enhance T cell therapies.

βš•οΈ Healthcare NASDAQ Listed 2020 € EUR
$1,000 invested 5 years ago β†’$580today

Score Overview

1 Year
Score
Net Growth-5.67%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-13.28%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.4
Net Growth-118.37%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth20.40%
Rev Trend40%
Revenue Consistencyβ€”
All Time
Score
Net Growth9.49%
Net Trend50%
Net Income Consistency
Rev Growth33.92%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Immatics NV has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IMTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 7.54β€”
1 Year2025-10-22
$ 10.13-25.57%
5 Years2021-10-22
$ 13.00-42.00%
All Time2020-07-02
$ 15.05-49.90%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 41M-€ 207M€ 393M
2025€ 48M-€ 196M€ 469M
2024€ 155M€ 15M€ 604M
2023€ 53M-€ 96M€ 425M
2022€ 172M€ 37M€ 362M
2021€ 34M-€ 95M€ 145M
IPO2020€ 31M-€ 229M€ 231M
IMTX - Immatics NV logo

Immatics NV fundamental performance

Between 2020 and 2025, revenue grew from € 31M to € 48M and net income went from -€ 229M to -€ 196M. Revenue increased in 2 of those 5 years; net income in 2.

Immatics NV currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.

Membership

Explore IMTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies